- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David Rosmarin on Tailored Biologic Treatments, New Vitiligo Research
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Transcript:
What are some best practices for choosing biologics for patients with different dermatological conditions?
For patients who come in to see us who have various conditions, we really try to tailor the biologic treatment to their needs. I don't have an algorithm where I always put every patient on drug X and then drug Y and then drug Z. I really try to hear what's most important to the patient. Is it certain side effects that they're having that they're worried about, or frequency of injections of medication? In that way, we can try to make sure that we give them the best possible treatment that meets their goals.
What can you tell us about your latest research on the efficacy and safety of ruxolitinib cream monotherapy for vitiligo?
So today [Saturday], we released the results of the TRuE-V1 and TRuE-V2 phase 3 program for topical ruxolitinib cream in vitiligo through Week 52. What it showed is that patients get enhanced pigmentation beyond the 6-month mark, with continued improvement through the year.
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
